## ADPT: Adaptive Biotechnologies Corpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -18.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-19.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($12.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares**
- Source: StocksToTrade | 20251207T212227 | Neutral | Relevance: 99%
- Adaptive Biotechnologies (ADPT) CEO Chad M. Robins sold over $3 million in company shares in recent weeks, including 160,734 shares in early December and 89,265 shares in mid-November. This insider selling coincides with a -15.52% stock decline and financial metrics showing operational inefficiencies despite strong revenue growth and liquidity. Analysts maintain a cautiously bearish outlook due to negative profit margins, high P/S ratio, and underperforming capital utilization.

**2. Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biotechnologies Corp (ADPT)**
- Source: GuruFocus | 20251207T001016 | Neutral | Relevance: 99%
-  Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (ADPT), sold 37,212 shares of the company on December 4, 2025. This transaction increases his total holdings to 1,232,312 shares. The stock is considered significantly overvalued based on its GuruFocus Value, with a price-to-GF-Value ratio of 2.1.

**3. Adaptive Biotechnologies (ADPT) Is Down 11.2% After Earnings Beat And CFO Share Sale - Has The Bull Case Changed?**
- Source: Simply Wall Street | 20251206T052227 | Neutral | Relevance: 99%
-  Adaptive Biotechnologies (ADPT) recently reported Q3 2025 results, beating expectations with US$94 million in revenue and 42.6% year-on-year growth, despite ongoing unprofitability. Concurrently, CFO Kyle Piskel sold 162,820 shares worth approximately US$3.17 million. This article examines how the earnings beat and insider sale, alongside raised 2025 MRD revenue guidance, impact the company's investment narrative, focusing on its growth trajectory versus execution risks and continued losses.

**4. Adaptive Biotechnologies Stock Declines After Insider Sale**
- Source: www.timothysykes.com | 20251207T162227 | Neutral | Relevance: 98%
-  Adaptive Biotechnologies (ADPT) stock declined by 15.52% following an insider share sale by CEO Chad M. Robins, amid market uncertainty and underperformance against Healthcare benchmarks. The company faces significant financial struggles with negative EBIT and profit margins, high debt-equity, and inefficiencies in converting investments into financial performance despite a robust current ratio and some revenue growth. This insider activity, combined with adverse financial indicators, contributes to market skepticism and a cautious outlook for the stock.

**5. Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025**
- Source: Stock Titan | 20251207T052227 | Bullish | Relevance: 98%
-  Adaptive Biotechnologies announced expanded clinical use of its clonoSEQ measurable residual disease (MRD) test at the 67th ASH Annual Meeting, highlighting 90 abstracts featuring clonoSEQ data, with 17 showing MRD-guided clinical interventions. The phase II EndRAD study notably reported outstanding event-free and overall survival in NGS MRD-negative B-ALL patients receiving non-TBI transplant conditioning. This news underscores clonoSEQ's leadership in blood cancer MRD monitoring and its role as a decision-making tool in treatment.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $16 | $11 | +45% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($1.13M) |
| Sells | 11 ($5.21M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_10 falling (-19.3% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $5.2M in recent transactions.
4. Elevated short interest (8.7%): bears positioning against stock.
5. Near-term weakness: 8.1% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Analyst sentiment positive (1 raises, avg +45%). Insider selling cluster ($5.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 2.20 |
| 52W Range | $5.80 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 0.6% to -18.7% (-19.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 21.7pp (needs >3.0% for momentum thesis). Underperforming sector by 15.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.28x) but short-term weakness (below SMA20). RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -18.70% (CS: 50) | Weak |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 0.902x | Below |
| vs SMA50 | 0.919x | Below |
| vs SMA200 | 1.282x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.95
- **Stop Loss:** $12.47 (16.6% risk)
- **Target:** $17.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 201
- **Position Value:** $3,004.95
- **Portfolio %:** 3.00%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*